Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. METHODS: In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC. Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed death ligand 1 (PD-L1), mutational burden, and mutation-associated, neoantigen-specific T-cell responses. RESULTS: Neoadjuvant nivolumab had an acceptable side-effect profile and was not associated with delays in surgery. Of the 21 tumors that were removed, 20 were completely resected. A major pathological response occurred in 9 of 20 resected tumors (45%). Responses occurred in both PD-L1-positive and PD-L1-negative tumors. There was a significant correlation between the pathological response and the pretreatment tumor mutational burden. The number of T-cell clones that were found in both the tumor and peripheral blood increased systemically after PD-1 blockade in eight of nine patients who were evaluated. Mutation-associated, neoantigen-specific T-cell clones from a primary tumor with a complete response on pathological assessment rapidly expanded in peripheral blood at 2 to 4 weeks after treatment; some of these clones were not detected before the administration of nivolumab. CONCLUSIONS: Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute-Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies examining the clinical activity of single agent anti-PD-1/PD-L1 therapies in the neoadjuvant setting have reported MPR rates between 19% and 45% in patients with resectable NSCLC14–16.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some studies have found that high TCR diversity in peripheral blood and tumors prior to ICI therapy is predictive of effective treatment, others have pointed to ICI therapy-associated increases in TCR clonality, that is, enrichment of T cells with the same TCRs, as a sign of effective therapy (150, 157-161).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, studies of neoadjuvant immunotherapy in patients with resectable NSCLC reported responses irrespective of PD-L114,21,”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cited by
Items 301–400 of 1,000
Eichhorn, F., Klotz, L. V., Bischoff, H. G., Thomas, M., Lasitschka, F., Winter, H., Hoffmann, H., & Eichhorn, M. (2019) · BMC Cancer · doi:10.1186/s12885-019-5624-2 · Cited by 76
Cell and tissue engineering in lymph nodes for cancer immunotherapy
Najibi, A. J., & Mooney, D. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.023 · Cited by 80
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 87
Stein, J. E., Soni, A., Danilova, L., Cottrell, T. R., Gajewski, T. F., Hodi, F. S., Bhatia, S., Urba, W. J., Sharfman, W. H., Wind-Rotolo, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz019 · Cited by 73
“The first clinical trials for neoadjuvant anti-PD-1 for patients with non-small cell lung carcinoma (NSCLC) and melanoma have recently been resulted [2, 3].”
BackgroundResultSelf-citationBiomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 79
Ulas, E. B., Dickhoff, C., Schneiders, F. L., Senan, S., & Bahce, I. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100244 · Cited by 76
“No surgical delay was reported in 6 of the 19 included studies.(13,15,19,20,22,23) Reported surgical delays were most often attributed to trAEs.”
BackgroundInfluentialAran, A., Garrigós, L., Curigliano, G., Cortés, J., & Martí, M. (2022) · Cancers · doi:10.3390/cancers14071771 · Cited by 81
Ooki, A., Osumi, H., Yoshino, K., & Yamaguchi, K. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01523-4 · Cited by 81
“Several trials have reported the promising treatment efficacy of neoadjuvant ICI in lung cancer, melanoma, bladder cancer, and CRC [191–195], indicating that immunotherapy may be highly effective in patients with early-stage cancer.”
BackgroundInterdisciplinary multimodality management of stage III nonsmall cell lung cancer
Huber, R. M., Ruysscher, D. D., Hoffmann, H., Reu, S., & Tufman, A. (2019) · European Respiratory Review · doi:10.1183/16000617.0024-2019 · Cited by 76
Aversa, I., Malanga, D., Fiume, G., & Palmieri, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072378 · Cited by 78
“This phenomenon supports the idea that the formation of T-cell clones committed against the tumor can expand to other tissues in order to fight micrometastasis, thereby providing a justification for the use of immune checkpoint inhibitors prior to surgery [75,98].”
BackgroundInfluentialThe right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy
Kwon, M., Jung, H., Nam, G., & Kim, I.-S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.009 · Cited by 78
Román, A. R., de la Cruz, J. L. C.-C., Macía, I., Campuzano, I. E., Almánzar, S. F., Roel, M. D., Muñoz, C. G., Fontán, E. M. G., Trueba, I. M., Laura, R. V., et al. (2021) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezab007 · Cited by 83
Jiang, J., Wang, Y., Gao, Y., Sugimura, H., Minervini, F., Uchino, J., Halmos, B., Yendamuri, S., Velotta, J. B., & Li, M. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-75 · Cited by 83
“Investigational ICIs included PD-1/ PD-L1 inhibitors such as nivolumab (13,18,25,27,28), pembrolizumab (16,20), sintilimab (15), durvalumab (26), atezolizumab (14,19), avelumab (23), and a CTLA-4 inhibitor ipilimumab (24).”
BackgroundResultInfluentialRen, X., Hui, Z., Zhang, J., Ren, Y., LI, X., Yan, C., Wang, T., Yu, W., Wang, T., Xiao, S., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05057-4 · Cited by 83
“PD-1 blockage given prior to surgical removal of NSCLC is safe and induced a major pathological response (MPR) in 45% of resected tumors, according to the first neoadjuvant immunotherapy trial for patients with early-stage lung cancer [5].”
BackgroundSelf-citationKim, S. S., Cooke, D. T., Kidane, B., Tapias, L. F., Lazar, J. F. L., Hayanga, J. W. A., Patel, J. D., Neal, J. W., Abazeed, M. E., Willers, H., et al. (2024) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2024.09.041 · Cited by 88
2018 Nobel Prize in physiology or medicine
Smyth, M. J., & Teng, M. W. L. (2018) · Clinical & Translational Immunology · doi:10.1002/cti2.1041 · Cited by 87
“One of the most important recent advances concerns the earlier use of ICI in neoadjuvant therapy in the context of surgery – and here the first results look extremely promising.(21,22) Indeed, it remains very early in the implementation of cancer immunotherapy into mainstream oncology practice and one would envisage f…”
ResultBatf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy
Liu, J., Rozeman, E. A., O’Donnell, J. S., Allen, S., Fanchi, L., Smyth, M. J., Blank, C. U., & Teng, M. W. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1546068 · Cited by 70
Gupta, S., Cheville, J. C., Jungbluth, A. A., Zhang, Y., Zhang, L., Chen, Y., Tickoo, S. K., Fine, S. W., Gopalan, A., Al‐Ahmadie, H. A., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0269-x · Cited by 76
Beyond PD-L1 Markers for Lung Cancer Immunotherapy
Wojas‐Krawczyk, K., Kalinka‐Warzocha, E., Grenda, A., Krawczyk, P. A., & Milanowski, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081915 · Cited by 79
Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC
Zhang, F., Guo, W., Zhou, B., Wang, S., Li, N., Qiu, B., Lv, F., Zhao, L., Li, J., Shao, K., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.04.012 · Cited by 73
Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy
Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419876351 · Cited by 69
Zhang, Y., Jiang, X., Zhang, N., Chen, M., Wang, H., & Zhu, D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.017 · Cited by 91
Self-citationTargeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications
Wang, D.-K., Zuo, Q., He, Q., & Li, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705999 · Cited by 74
Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors
Coakley, M., Garcia-Murillas, I., & Turner, N. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0152 · Cited by 69
Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer
Muthusamy, B., Patil, P. D., & Pennell, N. A. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7021 · Cited by 76
Yamamoto, S., Kato, K., Daiko, H., Kojima, T., Hara, H., Abe, T., Tsubosa, Y., Nagashima, K., Aoki, K., Mizoguchi, Y., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0189 · Cited by 71
Progress in advanced nanotherapeutics for enhanced photodynamic immunotherapy of tumor
Xiao, W., Song, M., Jiang, G., Liang, M., Chen, C., Yang, Z., & Zou, L. (2022) · Theranostics · doi:10.7150/thno.73566 · Cited by 69
“In the past decade, the clinical application of immune checkpoint inhibitors (ICIs) has greatly promoted the development of cancer immunotherapy [29-31].”
BackgroundCRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy
Salas-McKee, J., Kong, W., Gladney, W. L., Jadlowsky, J. K., Plesa, G., Suhoski, M. M., & Fraietta, J. A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571893 · Cited by 73
Fukuoka, E., Yamashita, K., Tanaka, T., Sawada, R., Sugita, Y., Arimoto, A., Fujita, M., Takiguchi, G., Matsuda, T., Oshikiri, T., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13631 · Cited by 66
Immune-based therapies in penile cancer
Joshi, V. B., Spiess, P. E., Necchi, A., Pettaway, C. A., & Chahoud, J. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00617-x · Cited by 70
Olivares-Hernández, A., Portillo, E. G.-D., Tamayo-Velasco, Á., Figuero-Pérez, L., Zhilina-Zhilina, S., Fonseca‐Sánchez, E., & Miramontes‐González, J. P. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4218 · Cited by 81
“Compared to adjuvant treatment, the neoadjuvant treatment enables the early control of the disease at the systemic level (29).”
Kaseb, A. O., Vence, L., Blando, J., Yadav, S. S., Ikoma, N., Pestana, R. C., Vauthey, J. N., Allison, J. P., & Sharma, P. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0605 · Cited by 67
T‐cell receptor and B‐cell receptor repertoire profiling in adaptive immunity
Minervina, A., Pogorelyy, M., & Mamedov, I. (2019) · Transplant International · doi:10.1111/tri.13475 · Cited by 65
Immunotherapy in non-small cell lung cancer: update and new insights
Mielgo-Rubio, X., Uribelarrea, E. A., Cortés, L. Q., & Moyano, M. S. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202101.001 · Cited by 78
“The primary objectives in most of these studies are OS and, in some cases, disease-free survival (DFS), thus leading to laborious studies that may only give us results once the therapy has become obsolete in this setting [13,27].”
BackgroundZhu, X., Sun, L., Song, N., He, W., Xie, B., Hu, J., Zhang, J., Yang, J., Dai, J., Bian, D., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02696-4 · Cited by 76
“The sample size was set as 50 patients, providing 80% power to detect an MPR of 44% [25] compared to 20% for neoadjuvant chemotherapy [26], with a surgical rate of 60% and a two-sided type I error of 5%.”
Self-citationNie, D., Ling, Y., Lv, W., Liu, Q., Deng, S., Shi, J., Yang, J., Yang, Y., Ouyang, S., Huang, Y., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c03696 · Cited by 66
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
Qiu, Z., Chen, Z., Zhang, C., & Zhong, W. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0143-z · Cited by 65
Konstantinopoulos, P. A., Lheureux, S., & Moore, K. N. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_288015 · Cited by 72
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease
Κhan, P., Siddiqui, J. A., Maurya, S. K., Lakshmanan, I., Jain, M., Ganti, A. K., Salgia, R., Batra, S. K., & Nasser, M. W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.006 · Cited by 69
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Li, T., Niu, M., Zhou, J., Wu, K., & Yi, M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01562-5 · Cited by 70
International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?
Putora, P. M., Leskow, P., McDonald, F., Batchelor, T. J. P., & Evison, M. (2020) · ERJ Open Research · doi:10.1183/23120541.00159-2019 · Cited by 68
Zhu, X., Li, K., & Sun, H. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.02.002 · Cited by 68
Lin, X., Huang, R., Huang, Y., Wang, K., Li, H., Bao, Y., Wu, C., Zhang, Y., Tian, X.-H., & Wang, X. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s290796 · Cited by 66
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern, E. S., Solomon, B., Hui, R., Pavlakis, N., O'Byrne, K. J., & Hughes, B. G. M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002248 · Cited by 70
“38 Vali-dating and integrating such investigations, which require sophisticated transcriptomic and in silico analysis, into the predictive algorithm when selecting appropriate patients for NAICI approaches at baseline is an emerging challenge.”
InfluentialTolba, M. F. (2020) · International Journal of Cancer · doi:10.1002/ijc.33056 · Cited by 73
Kim, H., Park, S., Han, K.-Y., Lee, N., Kim, H. M., Jung, H. A., Sun, J., Ahn, J. S., Ahn, M., Lee, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005509 · Cited by 74
Zhang, J., Cai, J. Q., Deng, Y., & Wang, H. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1663108 · Cited by 65
“In resectable lung cancer with neoadjuvant PD-1 blockade, some of the patients with tumor increasing in size were found to have minimal or no residual tumor in resected specimen.(12) This process occurs because of immune-cell infiltration into the tumor rather than true tumor growth.”
BackgroundSelf-citationOur current understanding of checkpoint inhibitor therapy in cancer immunotherapy
Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 64
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer
Mazzotti, L., Gaimari, A., Bravaccini, S., Maltoni, R., Cerchione, C., Juan, M., González‐Navarro, E. A., Pasetto, A., Silva, D. N., Ancarani, V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158590 · Cited by 70
“Interestingly, patients treated with the PD-1 inhibitor nivolumab start to develop antigen-specific T-cell clones 2–4 weeks after ICI treatment, suggesting that PD-1 signaling blockade promotes anti-tumoral T-cell-dependent activities that enhanced tumor antigen-driven priming of first resident and then circulating T-…”
BackgroundLi, C., Wu, J., Jiang, L., Zhang, L., Huang, J., Tian, Y., Zhao, Y., Liu, X., Xia, L., Haoran, E., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03262-w · Cited by 71
“In certain cases with MPR, the tumor diameter may even enlarge due to immune cell infiltration [2].”
BackgroundLi, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 76
“Immune checkpoint inhibitor (ICI), notably anti-PD-L1/ PD-1 antibody, is the cornerstone of immunotherapy for multiple cancer types including NSCLC. PD-1/PD-L1 binding leads to intratumoral T-cell exhaustion thus blocking this interaction may reactivate exhausted T-cells for cancer cell killing.”
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
Jafarnejad, M., Gong, C., Gabrielson, E., Bartelink, I. H., Vicini, P., Wang, B., Narwal, R., Roskos, L., & Popel, A. S. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0350-x · Cited by 62
Self-citationSmall molecules as theranostic agents in cancer immunology
Li, J., Valkenburgh, J. S. V., Hong, X., Conti, P. S., Zhang, X., & Chen, K. (2019) · Theranostics · doi:10.7150/thno.37218 · Cited by 65
“the immune system of patients to treat multiple cancers [2-6].”
BackgroundCurrent Surgical Indications for Non-Small-Cell Lung Cancer
Deboever, N., Mitchell, K. G., Feldman, H. A., Cascone, T., & Sepesi, B. (2022) · Cancers · doi:10.3390/cancers14051263 · Cited by 74
“[50,51] (PACIFIC) 2017–2018 Randomized Trial Unresectable Stage III 713 Consolidation therapy with durvalumab associated with better OS and PFS compared to placebo, regardless of PD-L1 expression”
BackgroundBai, R., Li, L., Chen, X., Chen, N., Song, W., & Cui, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.575472 · Cited by 62
“Neoadjuvant Monotherapy With Immune Checkpoint Inhibitors The CheckMate 159 study (11) was the first research to prospectively explore the feasibility and safety of neoadjuvant therapy with ICIs in 22 patients with treatment-naive and resectable stage I–IIIA NSCLC, with 20 patients [2 partial response (PR) and 18 stab…”
BackgroundResultInfluentialCurrent status and perspectives of immune checkpoint inhibitors for colorectal cancer
Hirano, H., Takashima, A., Hamaguchi, T., Shida, D., & Kanemitsu, Y. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa200 · Cited by 66
Godoy, L. A., Chen, J., Ma, W., Lally, J., Toomey, K. A., Rajappa, P., Sheridan, R., Mahajan, S., Stollenwerk, N. S., Phan, C. T., et al. (2023) · Biomarker Research · doi:10.1186/s40364-022-00444-7 · Cited by 74
Zhu, J., Yin, T., Xu, Y., & Lu, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28048 · Cited by 59
Biomarkers for immunotherapy for treatment of glioblastoma
Lynes, J. P., Nwankwo, A., Sur, H. P., Sanchez, V. E., Sarpong, K., Ariyo, O., Dominah, G. A., & Nduom, E. K.-E. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000348 · Cited by 63
Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival
Markowitz, G. J., Havel, L. S., Crowley, M. J. P., Ban, Y., Lee, S. B., Thalappillil, J. S., Narula, N., Bhinder, B., Elemento, O., Wong, S. T. C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96836 · Cited by 62
“These results clearly demonstrate the potential of targeting these patients, who still have a relatively poor prognosis (5-year survival ranging from 50% at stage IA to 20% at stage IIIA and frequent relapse after resection) but have a more intact immune system than advanced-disease patients (38).”
BackgroundImmunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
Berghmans, T., Durieux, V., Hendriks, L. E. L., & Dingemans, A. C. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00090 · Cited by 62
Shen, D., Wang, J., Wu, J., Chen, S., Li, J., Liu, J., Chen, Q., & Jiang, Y. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-103 · Cited by 62
“However, other researchers reported no such correlation (25-27).”
BackgroundResultInfluentialPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 57
“Evidence from clinical trials suggests the positive correlation between high tumor mutational loads and improved clinical efficacy of ICB-based therapies (including anti-PD-1, anti-PD-L1, and anti-CTLA-4) in NSCLC and melanoma (Snyder et al., 2014; Rizvi et al., 2015; Van Allen et al., 2015; Hugo et al., 2016; Forde e…”
BackgroundRodríguez, J., Álvarez, E. C., Perez‐Gracia, J. L., Rodríguez, I., Viúdez, A., Alfaro, C., Oñate, C., Pérez, G., Rotellar, F., Inogés, S., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0405-z · Cited by 64
Moya‐Plana, A., Auperin, A., Obongo, R., Baglin, A., Ferrand, F. R., BAUJAT, B., Saroul, N., Casiraghi, O., Vergèz, S., Herman, P., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.007 · Cited by 58
Liu, S., Knochelmann, H. M., Lomeli, S. H., Hong, A., Richardson, M. S., Yang, Z., Lim, R. J., Wang, Y., Dumitras, C., Krysan, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100411 · Cited by 66
Ling, Y., Li, N., Li, L., Guo, C., Wei, J., Yuan, P., Tan, F., Tao, X., Wang, S., Wang, Z., et al. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00135-2 · Cited by 62
Neoadjuvant immunotherapy for resectable esophageal cancer: A review
Li, Q., Liu, T., & Ding, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1051841 · Cited by 57
“Currently, ICI neoadjuvant therapy has been tried in a variety of tumors, such as lung cancer (18, 19), melanoma (20–23), bladder cancer (24), colon cancer (25) and glioblastoma (26, 27).”
BackgroundInfluentialIsla, D., Lozano, M. D., Paz-Ares, L. G., Salas, C., de Castro, J., Conde, E., Felip, E., Gómez‐Román, J., Garrido, P., & Enguita, A. B. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-03046-9 · Cited by 68
“More recently, PD-1/PD-L1 blockade has been shown to be also effective in the adjuvant and neo-adjuvant context in patients with early disease [38, 39].”
BackgroundEmiloju, O. E., & Sinicrope, F. A. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.3323 · Cited by 60
de Malet, A., Antoni, G., Collins, M., Soularue, É., Marthey, L., Vaysse, T., Coutzac, C., Chaput, N., Mateus, C., Robert, C., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.006 · Cited by 61
Early-Stage NSCLC: Advances in Thoracic Oncology 2018
Osarogiagbon, R. U., Veronesi, G., Fang, W., Ekman, S., Suda, K., Aerts, J. G. J. V., & Donington, J. S. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.029 · Cited by 60
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy
Dunn, G. P., Cloughesy, T. F., Maus, M. V., Prins, R. M., Reardon, D. A., & Sonabend, A. M. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa154 · Cited by 61
Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants
Arakawa, A., Ichikawa, H., Kubo, T., Motoi, N., Kumamoto, T., Nakajima, M., Yonemori, K., Noguchi, E., Sunami, K., Shiraishi, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030391 · Cited by 58
Raimondi, A., Palermo, F., Prisciandaro, M., Aglietta, M., Antonuzzo, L., Aprile, G., Berardi, R., Cardellino, G. G., Manzoni, G. D., Vita, F. D., et al. (2021) · Cancers · doi:10.3390/cancers13112839 · Cited by 57
“showed that two doses of the anti-PD-1 nivolumab (3 mg/kg every two weeks) in untreated, resectable (stage I-IIIA) tumors was safe and did not delay the planned surgery, while conferring a major pathological response in 9 out of 20 patients operated irrespectively of PD-L1 status, although the pre-treatment tumor muta…”
BackgroundFAM111B, a direct target of p53, promotes the malignant process of lung adenocarcinoma
Sun, H., Liu, K., Huang, J., Sun, Q., Shao, C., Luo, J., Xu, L., Shen, Y., & Ren, B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s190934 · Cited by 55
“Background Lung cancer is the most common type of malignant tumors worldwide and the incidence of lung cancer is still on the rise.(1) Non-small cell lung cancer (NSCLC) occupies 85% of lung cancer and includes two pathological types of lung cancer, namely lung adenocarcinoma (LUAD) and lung squamous carcinoma.”
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 62
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives
Larroquette, M., Peyraud, F., Domblides, C., Lefort, F., Bernhard, J., Ravaud, A., & Gross‐Goupil, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102207 · Cited by 65
Li, X., Fang, Q., Du, W., Zhang, X., Dai, L., & Qiao, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08373-8 · Cited by 54
“[30] noted that approximately half of the initially enrolled 28 patients showed a pathologic response > 10, 32% a major response > 70%, and one had pathologic complete response after one dose of pembrolizumab.”
BackgroundĐačić, S., Travis, W. D., Redman, M. W., Saqi, A., Cooper, W. A., Borczuk, A., Chung, J.-H., Glass, C., Martín-López, J., Roden, A. C., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.07.017 · Cited by 58
Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
Benítez, J. C., Remón, J., & Besse, B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3255 · Cited by 60
“In NSCLC, some studies reported no correlation between MPR and PD-L1 expression (28, 30, 37) or TMB (30), while others did (28, 31, 33).”
BackgroundLiang, H., Yang, C., González-Rivas, D., Zhong, Y., He, P., Deng, H., Liu, J., Liang, W., He, J., & Li, S. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-778 · Cited by 58
“The first of these studies was CHEKMATE 159 published in 2018 (14): two preoperative doses of PD-1 inhibitor nivolumab were administered to early (stage I, II, or IIIA) NSCLC patients intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose.”
BackgroundRytlewski, J. A., Deng, S., Xie, T., Davis, C. B., Robins, H. S., Yusko, E. C., & Bienkowska, J. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213684 · Cited by 53
Zheng, N., Wang, T., Luo, Q., Liu, Y., Yang, J., Zhou, Y., Xie, G., Ma, Y., Yuan, X., & Shen, L. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2210959 · Cited by 54
Wei, J., Lu, X., Liu, Q., Fu, Y. S., Liu, S., Zhao, Y., Zhou, J., Chen, H., Wang, M., Li, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40480-x · Cited by 56
“Although the survival bene fi t of neoadjuvant immunotherapy has been demonstrated in several solid tumors, including breast cancer 14 and hepatocellular carcinoma 15 , lung cancer 16 , and melanoma 17 , there is limited evidence in G/GEJ cancers.”
Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer
Liu, J., Jiao, X., & Gao, Q. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.04.015 · Cited by 56
The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells
Laba, S., Mallett, G., & Amarnath, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.022 · Cited by 57
Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease
Mittendorf, E. A., Burgers, F. H., Haanen, J. B. A. G., & Cascone, T. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349411 · Cited by 61
Low-avidity T cells drive endogenous tumor immunity in mice and humans
Singhaviranon, S., Dempsey, J. P., Hagymasi, A. T., Măndoiu, I., & Srivastava, P. K. (2025) · Nature Immunology · doi:10.1038/s41590-024-02044-z · Cited by 58
CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC)
Wald, O. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7100303 · Cited by 53
“In this scenario, researchers are looking both at the short-term effects of ICI on the tumor viability (as assessed by histological analysis of the resected tumor), and at the long-term effects of ICIs on disease recurrence rates [17].”
BackgroundThe Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer
Bryan, D. S., & Donington, J. S. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0624-7 · Cited by 52
Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications
Cappelli, L. C., & Bingham, C. O. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41587 · Cited by 53
“Initially, they were used only in advanced-stage cancer, but now adjuvant therapy in melanoma (5) is approved, and neoadjuvant therapy has shown efficacy for non–small cell lung cancer (6).”
MethodTherapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
Trojaniello, C., Luke, J. J., & Ascierto, P. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670726 · Cited by 58
“The primary site of the tumor can be used as a spring of antigens for the spread and activation of tumor-specific T cells and to control micro-metastases (32); however, optimal regimens have not been defined (33).”
BackgroundNeoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non–Small-Cell Lung Cancer
Passaro, A., Attili, I., & de Marinis, F. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00873 · Cited by 58
Rybkin, I. I., & Gadgeel, S. M. (2022) · Medical radiology · doi:10.1007/174_2022_313 · Cited by 51
Glorieux, C., Xia, X., You, X., Wang, Z., Han, Y., Yang, J. L., Noppe, G., de Meester, C., Ling, J., Robert, A. R., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.12.005 · Cited by 51
“In resectable lung cancer, nivolumab (PD-1 antibody) monotherapy could achieve complete responses in almost half of the cases [26], and therapeutic effects of combination of various chemotherapies (i.”
BackgroundSelf-citationPerioperative Immune Checkpoint Inhibition in Early-Stage Non–Small Cell Lung Cancer: A Review
Desai, A. P., Adashek, J. J., Reuss, J. E., West, H., & Mansfield, A. S. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5389 · Cited by 58
Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives
Lazzari, C., Spagnolo, C. C., Ciappina, G., Pietro, M. D., Squeri, A., Passalacqua, M. I., Marchesi, S., Gregorc, V., & Santarpía, M. (2023) · Current Oncology · doi:10.3390/curroncol30040280 · Cited by 62
Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions
Sheth, R. A., Wehrenberg-Klee, E. P., Patel, S. P., Brock, K. K., Fotiadis, N., & de Baère, T. (2024) · Radiology · doi:10.1148/radiol.232654 · Cited by 55
Dai, D., Chen, B., Feng, Y., Wang, W., Jiang, Y., Huang, H., & Liu, J. (2020) · Aging · doi:10.18632/aging.103235 · Cited by 58
“Some immunotherapies, such as programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors or cytotoxic T lymphocyte-associated antigen 4 (CTLA4) therapies, have shown an optimistic antitumor effect in melanoma [3, 4], lung cancer [5], gastrointestinal cancer [6] and ovarian cancer [7].”
Background
Metadata
- Authors
- Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., Battafarano, R. J., Velez, M. J., Rekhtman, N., Olah, Z., Naidoo, J., Marrone, K. A., Verde, F., Guo, H., Zhang, J., Caushi, J. X., Chan, H. Y., Sidhom, J.-W., Scharpf, R. B., White, J., Gabrielson, E., Wang, H., Rosner, G. L., Rusch, V., Wolchok, J. D., Merghoub, T., Taube, J. M., Velculescu, V. E., Topalian, S. L., Brahmer, J. R., & Pardoll, D. M.
- Affiliations
- Johns Hopkins University (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Forde, Patrick M.
- Chaft, Jamie E.
- Smith, Kellie N.
- Anagnostou, Valsamo
- Cottrell, Tricia R.
- Hellmann, Matthew D.
- Zahurak, Marianna
- Yang, Stephen C.
- Jones, David R.
- Broderick, Stephen
- Velez, Moises J.
- Rekhtman, Natasha
- Naidoo, Jarushka
- Marrone, Kristen A.
- Verde, Franco
- Guo, Haidan
- Zhang, Jiajia
- Caushi, Justina X.
- Sidhom, John-William
- Scharpf, Robert B.
- White, James
- Wang, Hao
- Rosner, Gary L.
- Rusch, Valerie
- Wolchok, Jedd D.
- Merghoub, Taha
- Taube, Janis M.
- Velculescu, Victor E.
- Topalian, Suzanne L.
- Brahmer, Julie R.
- Pardoll, Drew M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-24
- Volume
- 378
- Issue
- 21
- Pages
- 1976-1986
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6223617
- OpenAlex
- W2798160602
- Cited by
- 2,099
- References
- 33
- Citations by year
- 2026: 123 · 2025: 181 · 2024: 241 · 2023: 304 · 2022: 304 · 2021: 342 · 2020: 279 · 2019: 214 · 2018: 110
- FWCI
- 89.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- International Association for the Study of Lung Cancer
- LUNGevity Foundation
- MacMillan Foundation
- Lung Cancer Foundation of America
- National Cancer Institute (CA006973, CA121113, CA180950, CA193145, P30 CA006973, P30 CA008748, R01 CA142779, T32 CA193145)
- ECOG-ACRIN
- Commonwealth Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Bristol-Myers Squibb
- Bloomberg–Kimmel Institute for Cancer Immunotherapy
- Stand Up To Cancer (SU2C-AACR-DT1012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- neoadjuvant immunotherapy, anti-PD-1 therapy, nivolumab, resectable non-small cell lung cancer, early-stage lung cancer, pathological response, PD-L1 expression, tumor mutational burden, predictive biomarkers, treatment safety and feasibility
- MeSH terms
- Nivolumab, Adenocarcinoma, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Biopsy, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pilot Projects, Neoadjuvant Therapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.